Association of CA 15-3 and CEA with Clinicopathological Parameters In Patients With Metastatic Breast Cancer

Mahmoud, Zeinab M; Abd Elwahed, Sahar Aboalftoh; El Badry, Doaa S.; Mohammed, Ahmed N.

doi:10.21608/smj.2017.40972

Association of CA 15-3 and CEA with Clinicopathological Parameters In Patients With Metastatic Breast Cancer

Document Type : Original Article

Authors

¹ Department of clinical and chemical pathology, Sohag Faculty of Medicine, Sohag University.

² Department of Clinical and Chemical pathology, Faculty of Medicine, Sohag University.

³ Department of Clinical Pathology, Faculty of medicine, Sohag university.

⁴ Department of clinical pathology, Faculty of medicine, Sohag university.

10.21608/smj.2017.40972

Abstract

Background. Breast cancer is the most common cancer and the leading cause of cancer death for women, a third of women are diagnosed with breast cancer at a late stage when the disease has a poor prognosis. Serum tumor markers have been widely used as noninvasive tools for measuring treatment response, early diagnosis of recurrence and predicting prognosis. In breast cancer, the most widely used serum tumor markers are cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA). The aim of this study was to investigate the association of serum CA15-3 and CEA levels with clinicopathological parameters in patients diagnosed with metastatic breast cancer (MBC).
Patients and methods. This retrospective study was conducted on 50 patients who had used to predict response to chemotherapy in patients with metastatic breast cancer. The concentration of serum CA15-3 and CEA levels were measured using chemiluminescent enzyme immunoassays (ABBOTT ARCHITECT). The upper limits of normal for CA15-3 and CEA were 31.3 U/ml and 5 ng/ml, respectively.
Result. Of the 50 patients, elevated CA 15-3 and CEA levels at initial diagnosis of recurrence were identified in 37 (74%) and 32 (64%) patients, respectively. Elevated CA 15-3 and CEA levels were significantly associated with breast cancer molecular subtypes (P=0.005 and P=0.008, respectively). Elevated CA 15-3 level was correlated with bone metastasis (P=0.047).
Conclusion. CA 15-3 and CEA level elevation at initial diagnosis of recurrence were found to be associated with breast cancer molecular subtype; these serum tumor markers are frequently increased in the HER2-enriched and triple negative (TN) molecular subtypes of breast cancer.

References

1- Garcia M et al (2007). Global Cancer Facts & Figures. Atlanta, GA: American Cancer Society.

2- Sayer HG, Kath R, Kliche KO and Höffken K (2002): Premenopausal breast cancer: chemotherapy and endocrine therapy. Drugs 62: 202-520;38.

3- De Bono JS, Tolcher AW and Rowinsky EK (2003): The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. Breast Cancer Res 5: 154-159

4- Yonemori K, Katsumata N, Noda A, et al (2008): Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer. J Cancer Res Clin Oncol 134: 1199 -1206.

5- Lumachi F, Basso S, Brandes A, Pagano D and Ermani M (2004)

470, Pages 51–55 Relationship Between Tumor Markers CEA and CA 15-3, TNM Staging, Estrogen Receptor Rate and MIB-1 Index in Patients with pT1-2 Breast Cancer.

6- Hosseni S.M, Ramjoo S, Arvandi S.H and Barat T (2015). CEA and CA 15-3 Serum Level in Metastatic Breast Cancer and Its Correlation with Distant Metastasis. Biomedical & Pharmacology Journal; Vol. 8 :721-727

7- Shao Y, Sun X, He Y, Liu C, Liu H.

(2015) Elevated Levels of Serum Tumor

Markers CEA andCA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer. PLoS ONE 10(7).

8- Wu S.G, He Z.Y, Zhou J, Sun J.Y, Li F.Y, Lin Q, Guo L and Lin H.X(2014)

Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. The Breast; 23: 88- 93.

9-Geng Biao, Man-Man, Liang Xiao-, et al. (2015) Molecular and Clinical Oncology 3: 232-236.

10-Weigang Wang, Xiaoqin Xu, Baoguo Tian, et al (2017) The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer Clinica Chimica Acta Volume.